Michael O’Dwyer is a Clinician Scientist who specializes in hematologic oncology. Prof. O’Dwyer established and is the director of the Blood Cancer Network, Ireland (BCNI), and leads the development of Phase I trial capability in Ireland. Prof. O’Dwyer contributed to the clinical development of Imatinib, the first effective molecular targeted therapy.
Speaking on cellular therapies for multiple myeloma
Prof. O’Dwyer focuses on understanding translational glycobiology in cancer, reversing immune tolerance/suppression in the tumour microenvironment and the use and modification of natural killer (NK) cells as cell therapy for cancer. Prof. O’Dwyer specializes in multiple myeloma, lymphoma and chronic lymphocytic leukemia.